Barrow Hanley Mewhinney & Strauss LLC Takes $8.49 Million Position in Ralliant Corporation $RAL

Key Points

• Barrow Hanley Mewhinney & Strauss LLC acquired 115,350 Ralliant shares worth approximately $8.49 million, joining several other institutional investors that initiated positions during the second quarter.
• Ralliant reported quarterly EPS of $0.68, beating estimates by $0.05, on revenue of $567.8 million. The company issued fiscal 2026 EPS guidance of $2.76–$2.90 and declared a quarterly dividend of $0.05 per share.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $75.70, although CEO Tamara Newcombe and SVP Karen Bick recently sold shares under pre-arranged trading plans.

Barrow Hanley Mewhinney & Strauss LLC purchased a new position in shares of Ralliant Corporation (NYSE:RAL - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 115,350 shares of the company's stock, valued at approximately $8,493,000. Barrow Hanley Mewhinney & Strauss LLC owned about 0.10% of Ralliant at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in RAL. Globeflex Capital L P purchased a new stake in Ralliant in the second quarter valued at $623,000. First Nebraska Trust Co purchased a new position in Ralliant in the 2nd quarter valued at approximately $760,000. Bank of Nova Scotia purchased a new position in Ralliant in the second quarter valued at $16,964,000. Commerce Bank purchased a new position in shares of Ralliant in the 2nd quarter valued at about $748,000. Finally, Quantbot Technologies LP acquired a new position in Ralliant during the 2nd quarter worth approximately $5,301,000.

Ralliant Stock Performance

NYSE RAL opened at $63.72 on Monday. The firm has a market capitalization of $7.05 billion, a P/E ratio of -5.87, a P/E/G ratio of 2.36 and a beta of 1.61. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41. The business's 50-day simple moving average is $68.94 and its 200-day simple moving average is $55.94.

Ralliant (NYSE:RAL - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.05. The company had revenue of $567.80 million during the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts predict that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant's payout ratio is -1.84%.

Insiders Place Their Bets

In other news, CEO Tamara S. Newcombe sold 12,936 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the transaction, the chief executive officer directly owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the sale, the senior vice president directly owned 31,668 shares of the company's stock, valued at $2,280,096. The trade was a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Oppenheimer upped their price target on Ralliant from $50.00 to $65.00 and gave the company an "outperform" rating in a report on Wednesday, May 13th. Wall Street Zen upgraded Ralliant from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays upped their price objective on shares of Ralliant from $52.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. Zacks Research raised Ralliant from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, June 30th. Finally, Royal Bank Of Canada increased their price target on shares of Ralliant from $71.00 to $73.00 and gave the company a "sector perform" rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $75.70.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source